Photo credit: commons.wikimedia.org

— Warren Buffett

A five-year holding period is a useful test of whether a stock has rewarded patient capital through both price appreciation and dividends. For Stryker Corp (NYSE: SYK), a $10,000 investment made on 11/12/2021 and held through 11/11/2026 produced a positive total return, though the result was driven by a mix of moderate share-price gains and reinvested dividends rather than rapid multiple expansion.

Stryker is one of the largest medical technology companies, with major franchises in orthopaedics, medical and surgical equipment, and neurotechnology. That operating profile matters when evaluating long-term returns: demand is often supported by procedure volumes, hospital capital spending, aging demographics, and recurring replacement cycles, but valuation can still compress or expand meaningfully depending on the broader interest-rate and market backdrop.

SYK 5-Year Return Details

SYK 5-Year Return Details
Start date:	11/12/2021	$10,000 11/12/2021   $12,708 11/11/2026
End date:	11/11/2026
Start price/share:	$264.34
End price/share:	$318.79
Starting shares:	37.83
Ending shares:	39.87
Dividends reinvested/share:	$15.86
Total return:	27.10%
Average annual return:	4.91%
Starting investment:	$10,000.00
Ending investment:	$12,708.21

A $10,000 investment in Stryker stock over this five-year span grew to $12,708.21, assuming dividends were reinvested. That equates to a 27.10% total return and an annualized return of 4.91%. The ending value reflects both the increase in SYK’s share price and the incremental shares accumulated through dividend reinvestment.

What Drove the Return

The investment outcome came from two distinct sources:

• Share-price appreciation: SYK rose from $264.34 to $318.79 over the period.
• Reinvested dividends: Stryker paid a cumulative $15.86 per share in dividends during the holding period, increasing the investor’s share count from 37.83 to 39.87.

That distinction matters. Price return alone does not capture the full economics of ownership in a dividend-paying stock. Even for companies with modest starting yields, reinvested dividends can contribute meaningfully to compounding over multi-year periods, especially when the business continues to raise its payout over time.

For this analysis, dividend reinvestment is assumed at the closing price on each ex-dividend date. The figures cited above were computed with the Dividend Channel DRIP Returns Calculator.

How to Interpret the 5-Year Result

A 27.10% total return over five years is positive, but not especially high for an equity investment over a full market cycle. The result suggests that investors in Stryker were paid for staying invested, but that much of the company’s underlying business quality may already have been reflected in the 2021 starting valuation. In other words, business resilience and steady dividend growth can still produce only moderate shareholder returns if the entry point is demanding.

That is often a relevant consideration with large-cap medical technology companies. Businesses such as Stryker can benefit from durable competitive positions, specialized product portfolios, and switching costs embedded in clinical workflows. At the same time, they may trade at premiums because those traits are widely recognized, which can limit forward returns unless earnings and cash flow growth remain strong enough to support the valuation.

Dividend Yield and Yield on Cost

Based on the most recent annualized dividend rate of $3.52 per share, SYK has a current dividend yield of approximately 1.10% using the ending share price of $318.79.

It is also useful to look at yield on cost, which measures the current annual dividend relative to the original purchase price:

• Current annualized dividend: $3.52 per share
• Original purchase price: $264.34 per share
• Yield on cost: about 1.33%

Yield on cost is not a valuation metric, but it can help illustrate how dividend growth changes the income profile of a long-held position. In Stryker’s case, the yield on cost is higher than the current market yield because the dividend is being measured against the lower original share price rather than the stock’s later market value.

Key Takeaways From This Stryker Investment

• Stryker delivered a positive five-year total return, turning $10,000 into $12,708.21.
• The annualized return was 4.91%, indicating moderate compounding rather than outsized performance.
• Dividends supported the outcome by increasing the share count through reinvestment.
• The result underscores the importance of starting valuation, even in a high-quality medical device business.

For long-term investors evaluating SYK, the central question is not only whether Stryker remains a durable business, but also whether future earnings growth, margin performance, capital allocation, and valuation together can support stronger total returns over the next five years than those achieved since late 2021.

One more investment principle is worth keeping in mind:
“A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett